GlassScriptPhysician profile
Ali Rashidian
NPI 1740590298
$5,541.67
in general payments reported to CMS, 2019-2025
32 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $119 · 2021: $216 · 2022: $3,435 · 2023: $423 · 2024: $281 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815 · Education: $87.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.24 |
| Education | $87.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,524.15 | 2022 | |
| Intuitive Surgical, INC. | $1,518.37 | 2022 | |
| Glaxosmithkline, LLC. | $504.58 | 2019-2023 | Nucala |
| Genentech USA, INC. | $234.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $208.45 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.97 | 2019-2025 | Ofev |
| United Therapeutics Corporation | $145.61 | 2019-2025 | Orenitram, Tyvaso |
| Olympus America INC. | $123.29 | 2022 | |
| Insmed, INC. | $110.25 | 2021-2025 | Arikayce, Brinsupri |
| E.R. Squibb & Sons, L.L.C. | $109.87 | 2022 | |
| Astellas Pharma US INC | $106.86 | 2023-2024 | Cresemba |
| Sunovion Pharmaceuticals INC. | $100.84 | 2019 | |
| Merck Sharp & Dohme LLC | $87.47 | 2019-2023 | Zerbaxa, Recarbrio |
| Grifols USA, LLC | $56.27 | 2024 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $50.87 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45.33 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $45.22 | 2022 | |
| Pulmonx Corporation | $43.53 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Philips North America LLC | $36.28 | 2022-2024 | (8874) Incourage |
| Electromed, INC. | $33.16 | 2023-2025 | Smartvest |
| Ceribell, INC. | $31.62 | 2020 | |
| Baxter Healthcare | $29.03 | 2024 | Hillrom - Monarch Airway Clearance System |
| Allergan, INC. | $27.13 | 2019 | |
| Verona Pharma, INC. | $26.58 | 2025 | Ohtuvayre |
| Amgen INC. | $25.98 | 2024 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $25.01 | 2023 | Uptravi |
| Ani Pharmaceuticals, INC. | $23.97 | 2023 | Purified Cortrophin Gel |
| Abbvie INC. | $23.00 | 2021 | |
| Mylan Specialty L.P. | $21.17 | 2023 | Yupelri |
| Ekos Corporation | $20.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.25 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Rashidian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.